MOUNTAIN VIEW, Calif.,
Jan. 9, 2017 /PRNewswire/
-- IRIDEX Corporation (Nasdaq: IRIX) today reported
preliminary revenues of approximately $12.4
to $12.5 million and $46.0 to $46.1
million for the fourth quarter and full year 2016,
respectively, meeting the previously provided quarterly and full
year guidance provided by the Company. Revenue growth
compared to fourth quarter and full year 2015 was driven by the
Company's new flagship Cyclo G6™ glaucoma laser platform that is
powered by the Company's proprietary MicroPulse™ technology. For
the 2016 fourth quarter, the Company sold approximately 96 Cyclo
G6™ glaucoma laser systems and shipped approximately 8,000 G6
probes.
"The G6 platform continues to outperform our expectations in
terms of both systems sold and disposable probe utilization.
The G6 platform is rapidly transforming our business and the
treatment of glaucoma as evidenced by continued strong market
acceptance of our products and clinical feedback from our
customers," stated William M. Moore,
President and CEO.
The Company expects to release its complete fourth quarter and
full year 2016 results in early March
2017, at which time, the Company will provide guidance for
full year 2017.
About IRIDEX
IRIDEX Corporation was founded in 1989
and is a worldwide leader in developing, manufacturing, and
marketing innovative and versatile laser-based medical systems,
delivery devices and consumable instrumentation for the
ophthalmology market. We maintain a deep commitment to the success
of our customers, with comprehensive technical, clinical, and
service support programs. IRIDEX is dedicated to a standard of
excellence, offering superior technology for superior results.
IRIDEX products are sold in the United
States through a direct sales force and internationally
through a combination of a direct sales force and a network of
approximately 70 independent distributors into over 100 countries.
For further information, visit the IRIDEX website at
http://www.iridex.com/.
Safe Harbor Statement
This announcement contains
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Act of 1934, as amended, including those statements
concerning its anticipated revenues for the quarter ended
December 31, 2016, the timing of the
release of the Company's complete financial results for 2016 fourth
quarter and full year, market acceptance of and clinical feedback
related to the Cyclo G6 platform, and the impact of the Cyclo
G6 platform on the Company's business. These statements are
not guarantees of future performance and actual results may differ
materially from those described in these forward-looking statements
as the result of a number of factors, including accounting
adjustments made by the Company in the process of closing the 2016
fourth quarter, risks associated with the sale, development and
production of Company products, and changes in the industries in
which the Company operates. Please see a detailed description
of the risks to the Company contained in the Company's Annual
Report on Form 10-K for the fiscal year ended January 2, 2016, and Quarterly Reports on Form
10-Q for subsequent fiscal quarters, each of which was filed with
the Securities and Exchange Commission, and the prospectus filed by
the Company with the Securities and Exchange Commission pursuant to
Rule 424(b) on December 9, 2016.
Forward-looking statements contained in this announcement are made
as of this date and will not be updated.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/iridex-announces-preliminary-unaudited-revenues-for-2016-fourth-quarter-and-full-year-300387469.html
SOURCE IRIDEX Corporation